Enanta Pharmaceuticals to Present at Jefferies 2014 Global Healthcare Conference
May 22 2014 - 8:30AM
Business Wire
Presentation to be Webcast on June 2, 2014
at 8:30 A.M. ET
Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and
development-focused biotechnology company dedicated to creating
small molecule drugs in the infectious disease field, today
announced that Jay R. Luly, Ph.D., President and Chief Executive
Officer, will present on Monday, June 2, 2014, at 8:30 a.m. ET
during the Jefferies 2014 Global Healthcare Conference taking place
in New York.
A live webcast and replay of the presentation can be accessed by
visiting the “Calendar of Events” section on the “Investors” page
of Enanta’s website at www.enanta.com. A replay of the webcast will
be available following the presentation and will be archived for
approximately 30 days.
About Enanta
Enanta Pharmaceuticals is a research and development-focused
biotechnology company that uses its robust chemistry-driven
approach and drug discovery capabilities to create small molecule
drugs in the infectious disease field. Enanta is discovering, and
in some cases developing, novel inhibitors designed for use against
the hepatitis C virus (HCV). These inhibitors include members of
the direct acting antiviral (DAA) inhibitor classes – protease
(partnered with AbbVie), NS5A (partnered with Novartis) and
nucleotide polymerase – as well as a host-targeted antiviral (HTA)
inhibitor class targeted against cyclophilin. Additionally, Enanta
has created a new class of antibiotics, called Bicyclolides, for
the treatment of multi-drug resistant bacteria, with a focus on
developing an intravenous and oral treatment for hospital and
community MRSA (methicillin-resistant Staphylococcus aureus)
infections.
Investor ContactEnanta Pharmaceuticals, Inc.Carol Miceli,
617-607-0710cmiceli@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Apr 2023 to Apr 2024